{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:26:43Z","timestamp":1786778803335,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Xiamen Municipal Healthcare Guidance Project","award":["No. 3502Z20209133"],"award-info":[{"award-number":["No. 3502Z20209133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04756-8","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:55:48Z","timestamp":1786776948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features"],"prefix":"10.1007","volume":"91","author":[{"given":"Jinsong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8774-1857","authenticated-orcid":false,"given":"Weihong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"issue":"11","key":"4756_CR1","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.3390\/ijms26115173","volume":"26","author":"A Forma","year":"2025","unstructured":"A. Forma et al., Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies. Int. J. Mol. Sci. 26(11), 5173 (2025)","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"4756_CR2","first-page":"425","volume":"331","author":"L Boucai","year":"2024","unstructured":"L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid Cancer: Rev. JAMA 331(5), 425\u2013435 (2024)","journal-title":"Thyroid Cancer: Rev. JAMA"},{"key":"4756_CR3","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.drup.2023.100939","volume":"68","author":"Y Liu","year":"2023","unstructured":"Y. Liu et al., Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resist. Updat. 68, 100939 (2023)","journal-title":"Drug Resist. Updat"},{"key":"4756_CR4","doi-asserted-by":"crossref","unstructured":"P.Z. Han et al., A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI Insight. 9(8), e173712 (2024)","DOI":"10.1172\/jci.insight.173712"},{"issue":"12","key":"4756_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00262-025-04210-0","volume":"74","author":"J Seok","year":"2025","unstructured":"J. Seok et al., Tumor microenvironment remodeling across thyroid cancer differentiation states revealed by spatial transcriptomics. Cancer Immunol. Immunother. 74(12), 357 (2025)","journal-title":"Cancer Immunol. Immunother"},{"issue":"1","key":"4756_CR6","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/s41467-021-26343-3","volume":"12","author":"W Pu","year":"2021","unstructured":"W. Pu et al., Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat. Commun. 12(1), 6058 (2021)","journal-title":"Nat. Commun."},{"issue":"10","key":"4756_CR7","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Y. Wu et al., FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 12(10), 4564\u20134580 (2022)","journal-title":"Theranostics"},{"issue":"1","key":"4756_CR8","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1038\/s41598-019-44361-6","volume":"9","author":"L Fozzatti","year":"2019","unstructured":"L. Fozzatti et al., Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression. Sci. Rep. 9(1), 8028 (2019)","journal-title":"Sci. Rep."},{"issue":"20","key":"4756_CR9","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.3390\/ijms232012578","volume":"23","author":"E Shin","year":"2022","unstructured":"E. Shin, J.S. Koo, Cell Component and Function of Tumor Microenvironment in Thyroid Cancer. Int. J. Mol. Sci. 23(20), 12578 (2022)","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"4756_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/s12885-024-12459-4","volume":"24","author":"Y Wang","year":"2024","unstructured":"Y. Wang et al., Pathomics and single-cell analysis of papillary thyroid carcinoma reveal the pro-metastatic influence of cancer-associated fibroblasts. BMC Cancer. 24(1), 710 (2024)","journal-title":"BMC Cancer"},{"issue":"7","key":"4756_CR11","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.7150\/thno.94207","volume":"14","author":"X Jin","year":"2024","unstructured":"X. Jin et al., Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling. Theranostics. 14(7), 3014\u20133028 (2024)","journal-title":"Theranostics"},{"issue":"4","key":"4756_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00204-024-03681-x","volume":"98","author":"H Tang","year":"2024","unstructured":"H. Tang et al., ATF4 in cellular stress, ferroptosis, and cancer. Arch. Toxicol. 98(4), 1025\u20131041 (2024)","journal-title":"Arch. Toxicol."},{"issue":"10","key":"4756_CR13","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.immuni.2025.09.003","volume":"58","author":"CDM Alicea Pauneto","year":"2025","unstructured":"C.D.M. Alicea Pauneto et al., Intra-tumoral hypoxia promotes CD8(+) T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 58(10), 2489\u20132504 (2025). e8","journal-title":"Immunity"},{"issue":"1","key":"4756_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41420-025-02683-7","volume":"11","author":"X Yan","year":"2025","unstructured":"X. Yan, C. Liu, The ATF4-glutamine axis: a central node in cancer metabolism, stress adaptation, and therapeutic targeting. Cell. Death Discov. 11(1), 390 (2025)","journal-title":"Cell. Death Discov"},{"issue":"1","key":"4756_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1021\/jacs.4c11146","volume":"147","author":"T Dong","year":"2025","unstructured":"T. Dong et al., G3BP1\/2-Targeting PROTAC Disrupts Stress Granules Dependent ATF4 Migracytosis as Cancer Therapy. J. Am. Chem. Soc. 147(1), 446\u2013461 (2025)","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"4756_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41419-021-03574-2","volume":"12","author":"L Wei","year":"2021","unstructured":"L. Wei et al., Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-beta1\/SMAD2\/3 pathway and ABCC1 transactivation. Cell. Death Dis. 12(4), 334 (2021)","journal-title":"Cell. Death Dis."},{"issue":"1","key":"4756_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41419-025-07588-y","volume":"16","author":"EG Sun","year":"2025","unstructured":"E.G. Sun et al., FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer. Cell. Death Dis. 16(1), 424 (2025)","journal-title":"Cell. Death Dis."},{"key":"4756_CR18","doi-asserted-by":"publisher","first-page":"633453","DOI":"10.3389\/fphar.2021.633453","volume":"12","author":"Y Liu","year":"2021","unstructured":"Y. Liu et al., Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer. Front. Pharmacol. 12, 633453 (2021)","journal-title":"Front. Pharmacol."},{"issue":"1","key":"4756_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"M. Xie et al., FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J. Hepatol. 79(1), 109\u2013125 (2023)","journal-title":"J. Hepatol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04756-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:55:50Z","timestamp":1786776950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04756-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4756"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04756-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Animal Ethical and Welfare Committee (AEWC) of Guangzhou Miles Biosciences (Approval No. MIS2026006) and were performed in accordance with institutional guidelines for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"273"}}